TRANSDERM SCOP Rx
Generic Name and Formulations:
Scopolamine 1.5mg (delivers approximately 1mg over 3 days); transdermal patch.
Novartis Consumer Health
Indications for TRANSDERM SCOP:
Prevention of motion sickness and post-op nausea and vomiting.
Apply to dry skin behind ear; do not cut patch. Motion sickness: 1 patch at least 4 hours before travel; remove after 72 hours. Post-op: 1 patch evening before surgery; for cesarean section: 1 patch 1 hour before surgery. Remove 24 hours after surgery.
Narrow angle glaucoma. Allergy to belladonna alkaloids.
Wash hands and skin after use; avoid eyes. GI or urinary tract obstruction. Hepatic, renal, or metabolic dysfunction. Seizure. Psychosis. Elderly. Pregnancy (Cat.C). Nursing mothers.
Alcohol, other CNS depressants potentiate CNS depression. Additive anticholinergic effects with other anticholinergics, antihistamines (e.g., meclizine), antidepressants. May affect absorption of other drugs.
Dry mouth, drowsiness, blurred vision, disorientation, confusion, difficult urination; withdrawal symptoms may occur if used for >3 days.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Triiodothyronine in the Treatment of Bipolar Depression
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Examining Rates of Long-Term Opioid Use in Youth With Psychiatric Disorders
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Researchers Identify Novel Potential Biomarkers for Autism
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Personal Health Information Found in Recycling
- Nightmares in Military Personnel Frequently Comorbid With Mental Health Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Addressing Racial Disparities in Bipolar Disorder Treatment
- Negative Symptoms Increase Cardiovascular Risk in Schizophrenia